Why are Sterile Fill Finish Processes Becoming Trendier?

Prefilled syringe products, IV drugs, and injectable pharmaceuticals, commonly known as parenteral drug products, have been rising compared to oral formulations. The primary reason for the quick increase in injectables over tablets or pills is that the administration of drugs has a greater bioavailability for the administered API, where active pharmaceutical ingredients are part of the drug formulation having a therapeutic effect on the body.

This blog discusses some reasons for the rapid popularity of sterile fill finish manufacturing. Kindly scroll down and continue reading to learn more.

 

Growth in the CDMO Industry

Greater bioavailability of the active pharmaceutical ingredient means that not much drug is needed to have a therapeutic effect on a patient. And low patient drug administration results in a lower risk of side effects and its severity for patients.

The less active pharmaceutical ingredient also reduces the drug production cost per treatment. This means that there are both monetary and physiological benefits to parenteral drugs with regard to bioavailability. Sterile fill-finish processes are the sterile wants for injectable medicine formulations. Aseptic fill finish processes are of two types. One of these processes is non-aseptic filling. While the other is an aseptic fill-finish that is in line with all Food and Drug Administration guiding principles for aseptic processes.

It is expected that the CDMO industry will continue to grow in the areas of lyophilization and fill-finish to support the increase in parenteral drug product manufacturing.

Next, we shall discuss a few factors that can be connected to the increase in the trendiness of sterile fill finish for products such as biological products.

 

Reasons for the Rise in Sterile Drug Fill Finish Processes

Below are three reasons for the rise in sterile fill finish processes.

 
1. Increase in Rare Disease Treatments

Several pharmaceutical companies have moved their focus from creating blockbuster drugs to developing orphan drugs used for the treatment of rare diseases. This change in focus is chiefly due to Federal incentives from ODA (the Orphan Drug Act) enacted in 1983.

Often these orphan drugs require parenteral drug formulations. With the Orphan Drug Act supporting the private sector’s development of drugs that treat diseases, many new rare disease treatments have been manufactured.

 
2. Increase in Injectable Pharmaceuticals

Forty-eight new molecular entities were approved by the Food and Drug Administration in 2019; of this forty-eight, twenty were parenteral drugs representing forty-two percent of NME approvals. In the following year, injectables was connected to forty-nine percent of NME endorsements, with 26 out of 53 Food and Drug Administration-approved NMEs being injectables.

 
3. A rise in the Use of Prefilled Syringes Usage

Lately, there has been a rise in healthcare usage of prefilled syringes. There has been an increase in the popularity of prefilled syringes as they reduce contamination risk, constantly deliver correct dosages, and are easy to administer to patients.

With these merits, prefilled syringes will most likely continue to increase in popularity, as well as the expanding worldwide parenteral drugs market.

At AbbVie, we are the leading company in pharmaceutical fill finish. Contact us today for your fill-finish solutions.